Vytrus Biotech (XMAD:VYT) ROCE %: 25.14% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:VYT Vytrus Biotech SA XMAD:VYT
66 GF Score
Price €15.60
GF Value €5.67
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech ROCE %?

Vytrus Biotech XMAD:VYT +4.00% 66 ROCE % is 25.14% as of Dec. 2025. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.67 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vytrus Biotech's annualized ROCE % for the quarter that ended in Dec. 2025 was 25.14%.

Vytrus Biotech  (XMAD:VYT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vytrus Biotech ROCE % Related Terms

Vytrus Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech ROCE % Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 7.20 9.84 6.03 11.05 27.96

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.88 11.78 9.83 30.92 25.14
XMAD:VYT
66GF Score
Vytrus Biotech SA XMAD:VYT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech ROCE % Calculation

Vytrus Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3.182/( ( (11.132 - 1.253) + (14.663 - 1.777) )/ 2 )
=3.182/( (9.879+12.886)/ 2 )
=3.182/11.3825
=27.96 %

Vytrus Biotech's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=3.062/( ( (13.17 - 1.693) + (14.663 - 1.777) )/ 2 )
=3.062/( ( 11.477 + 12.886 )/ 2 )
=3.062/12.1815
=25.14 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 25.14% mean?
Vytrus Biotech (XMAD:VYT) has a ROCE % of 25.14% as of Dec. 2025.
Is Vytrus Biotech's ROCE % too high?
Vytrus Biotech's current ROCE % is 25.14%. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's ROCE % compare to VRTX and REGN?
Vytrus Biotech's ROCE % of 25.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vytrus Biotech's current ROCE % is 25.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.67, compared to a current price of €15.60 — trading 175.1% above its estimated fair value. The current ROCE % is 25.14%. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current ROCE % is 25.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €15.60 is trading 175.1% above its estimated GF Value™ of €5.67. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • ROCE %: 25.14%
  • GF Value™: €5.67 vs. price of €15.60 (175.1% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score

Get the complete analysis for XMAD:VYT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.60
Price
€5.67
GF Value